Coagulopathy and embolic signal in cancer patients with ischemic stroke

Annals of Neurology

Volumn 68, Issue 2, 2010, Pages 213-219

  Seok, Jin Myoung ^a   Kim, Seon Gyeong ^a,b   Kim, Ji Won ^a   Chung, Chin Sang ^a   Kim, Gyeong Moon ^a   Lee, Kwang Ho ^a   Bang, Oh Young ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Namyangju Hanyang General Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; D DIMER;

ADENOCARCINOMA; ADULT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN EMBOLISM; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DIFFUSION WEIGHTED IMAGING; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STROKE PATIENT;

EID: 77955293003     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.2205     Document Type: Article

References (28)

1. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 1985;64:16-35.
2. Kim SG, Hong JM, Kim HY, et al. Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke 2010;41:798-801.
3. Rogers LR. Cerebrovascular complications in patients with cancer. Semin Neurol 2004;24:453-460.
4. Terashi H, Uchiyama S, Iwata M. Stroke in cancer patients [in Japanese]. Brain Nerve 2008;60:143-147.
5. Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand 2009;119:1-16.
6. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003;349:109-111.
7. Cestari DM, Weine DM, Panageas KS, et al. Stroke in patients with cancer: incidence and etiology. Neurology 2004;62:2025-2030.
8. Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke 1994;25:1215-1218.
9. Zhang YY, Cordato D, Shen Q, et al. Risk factor, pattern, etiology and outcome in ischemic stroke patients with cancer: a nested case-control study. Cerebrovasc Dis 2007;23:181-187.
10. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
11. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
12. Poppert H, Sadikovic S, Sander K, et al. Embolic signals in unselected stroke patients: prevalence and diagnostic benefit. Stroke 2006;37:2039-2043. (Pubitemid 44309901)
13. Grosset DG, Georgiadis D, Abdullah I, et al. Doppler emboli signals vary according to stroke subtype. Stroke 1994;25:382-384. (Pubitemid 24047264)
14. Molloy J, Markus HS. Asymptomatic embolization predicts stroke and TIA risk in patients with carotid artery stenosis. Stroke 1999;30:1440-1443. (Pubitemid 29296074)
15. Kaposzta Z, Young E, Bath PM, Markus HS. Clinical application of asymptomatic embolic signal detection in acute stroke: a prospective study. Stroke 1999;30:1814-1818. (Pubitemid 29411820)
16. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233-2240.
17. Packer RJ, Rorke LB, Lange BJ, et al. Cerebrovascular accidents in children with cancer. Pediatrics 1985;76:194-201.
18. Wilde JT, Kitchen S, Kinsey S, et al. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Br J Haematol 1989;71:65-70. (Pubitemid 19047699)
19. Lee AY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med 1999;131:417-423.
20. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780-1789.
21. Wada H, Kobayashi T, Abe Y, et al. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost 2006;4:1253-1258. (Pubitemid 43756702)
22. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349:1227-1235.
23. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002;86:389-395. (Pubitemid 34185123)
24. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003;97:3044-3052. (Pubitemid 36676259)
25. Blackwell K, Hurwitz H, Lieberman G, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004;101:77-82.
26. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32:2575-2579.
27. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-949.
28. Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009;29:316-320.